Skip to main content

Cardiovascular care in pediatric cancer survivors

Improved survival in pediatric oncology has highlighted the growing burden of cancer treatment-related cardiotoxicity. Delve into the recent advances and emerging priorities in this setting.

Read more

Editor's Choice

Pancreatic cancer and the gut microbiome

Explore current insights into microbiota–immune interactions in pancreatic cancer, microbiome-targeted therapeutic strategies, and promising approaches to enhance immunotherapy outcomes.

Baseline fatigue linked to worse toxicity from cancer treatments

Among people with cancer, the presence of fatigue before starting treatment is associated with an increased risk for severe, life-threatening, or fatal adverse events.

Primary leiomyosarcoma of the colon

Colonic leiomyosarcoma is a rare and aggressive tumor that is often difficult to diagnose preoperatively, especially in a case such as this where multiple biopsies were inconclusive.

Is functional cure possible in autoimmune diseases?

Research suggests this is achievable in selected cases through trigger removal, immune reset, or profound immune depletion. But advancing this paradigm requires standardized definitions, predictive biomarkers, and long-term trials.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

2025 ASH Congress hub

Catch up on all the latest news, guidance and expert opinion from the 2025 ASH annual meeting, including updates in sickle cell disease, multiple myeloma, lymphoma, transplants.

Read more

Are you up to date on targeted therapies for relapsed/refractory AML? 

Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.

Supported by: independent educational grant from Rigel

Find out more
SPONSORED

Masterclass webinar: Expert review of CAR T-cell therapy patient cases in R/R DLBCL or R/R FL

Join Professor Joy Ho as she leads a panel of Asia-Pacific-based experts, discussing real-life patient cases and their experiences with CAR T-cell therapy for the treatment of R/R DLBCL or R/R FL. Learn about how to identify appropriate patients for CAR T-cell therapy and how to optimize outcomes with this treatment modality. Gain insights into essential aspects of pre- and post-infusion management, as well as important considerations for treatment sequencing.

This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.

Sponsored by:
  • Novartis Pharma AG
Prof. Joy Ho
Prof. William Hwang
Dr. Kentaro Fukushima
Prof. Dok Hyun Yoon
Prof. Miki Ando
Developed by: Springer Health+
Learn more
Video

Case Studies

Primary leiomyosarcoma of the colon

Colonic leiomyosarcoma is a rare and aggressive tumor that is often difficult to diagnose preoperatively, especially in a case such as this where multiple biopsies were inconclusive.

Hodgkin lymphoma in a patient with Behçet disease

A case illustrating a rare but important association between Behçet disease and Hodgkin lymphoma, possibly mediated by immune dysregulation and chronic immunosuppression.

Fallopian tube teratoma underlying autoimmune encephalitis

A 32-year-old woman presented with overlapping anti-NMDA-R and anti-GFAP encephalitis refractory to immunotherapy due to an occult neoplasm, emphasizing the importance of searching for underlying tumors in treatment-resistant cases.

Keynote webinar | Spotlight on progress in colorectal cancer

On-demand video coming soon

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Prof. Antoni Castells
Prof. Harpreet Wasan
Prof. Edward Giovannucci
Notify me

Current Reviews

Antiemetic therapy

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor …

Bridging the gap: targeted treatment strategies for cancer of unknown primary

The advent of comprehensive genomic profiling has revolutionized not only the identification of the tissue of origin in cancer of unknown primary (CUP) but also enabled the detection of potentially actionable molecular alterations. Recent evidence …

Quality of cancer-related data from the Danish National patient registry (1994–2025) and the Danish cancer registry (2004–2025): a systematic review

The Danish National Patient Registry (DNPR) and the Danish Cancer Registry (DCR) are central to registry-based cancer research. This systematic review evaluates studies assessing the quality of cancer-related data in these registries under their …

Maternal hormonal contraception use and childhood cancer risk: a systematic review and meta-analysis

Observational studies have linked maternal hormonal contraception use to childhood cancer risk, but findings are inconsistent. A systematic review was conducted of this potential relationship. A systematic search was performed in PubMed, Embase …

Episode 22: Celebrating 25 years of TKIs in CML

Marking a major milestone in chronic myeloid leukemia treatment

Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.

In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.

Dr. Jorge Cortes
Listen now
Podcast

CME & eLearning

SPONSORED

Masterclass webinar: Expert review of CAR T-cell therapy patient cases in R/R DLBCL or R/R FL

Professor Joy Ho and a panel of Asia-Pacific-based experts will examine real-life patient cases in this Masterclass, exchanging insights into their clinical experiences of using CAR T-cell therapy to treat patients with R/R DLBCL or R/R FL.

This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.

Sponsored by:
  • Novartis Pharma AG
SPONSORED

CAR T-cell therapy medical education hub

This hub presents a curated selection of educational materials focused on the latest clinically relevant topics related to the use of chimeric antigen receptor (CAR) T‑cell therapy for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and R/R follicular lymphoma (FL).

This content has been developed in collaboration with and funded by the sponsor Novartis Pharma AG and is not intended for healthcare professionals based in the UK and US.

Sponsored by:
  • Novartis Pharma AG

The AML expert series

Hear directly from experts in acute myeloid leukemia about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME

Further Reading

Antiemetic therapy

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor …

Bridging the gap: targeted treatment strategies for cancer of unknown primary

The advent of comprehensive genomic profiling has revolutionized not only the identification of the tissue of origin in cancer of unknown primary (CUP) but also enabled the detection of potentially actionable molecular alterations. Recent evidence …

Related topics

Cardiovascular care in pediatric cancer survivors

Improved survival in pediatric oncology has highlighted the growing burden of cancer treatment-related cardiotoxicity. Delve into the recent advances and emerging priorities in this setting.

Read more
Image Credits
Red heart on an electrocardiogram trace/© manassanant / Stock.adobe.com, Conceptual illustration of gut microbiome/© ArtemisDiana / Getty Images / iStock, Older man sitting on the edge of a bed/© andreswd / E+ / Getty Images (symbolic image with model), Colonoscopy of patient with primary leiomyosarcoma of the colon/© 2025, Dae Hee Pyo et al, World J Surg Onc, Question mark made of pills/© Nadzeya / stock.adobe.com, Blood cells in abstract design/© zketch / Stock.adobe.com, Mammogram image on a screen/© Valerii Apetroaiei / stock.adobe.com, Close-up of subcutaneous injection syringe/© Laures / Getty Images / iStock, CAR T-cell attacking cancer cells/© LoveLive/stock.adobe.com, FDG PET-CT of patient with Behçet disease and Hodgkin lymphoma/© 2025, Matthew Coulter et al, under exclusive licence to International League of Associations for Rheumatology (ILAR), Clin Rheumatol, Teratoma of the fallopian tube in a patient with autoimmune encephalitis/© 2025, María Rivera Sánchez et al, BMC Neurol, Colon cancer illustration/© (M) KATERYNA KON / SCIENCE PHOTO LIBRARY / Getty Images, Medicine Matters Podcast promo image/© Springer Medizin GmbH, T-cell expressing chimeric antigen receptor (CAR) in the cell membrane; DNA is exposed from the T-cell to highlight the genetic engineering involved in creating CAR T-cells/© LoveLive/stock.adobe.com, Leukemia background in bright colors, including white and red blood cells in realistic style/© Double Brain/Shutterstock.com, Fundus scan in vitreoretinal lymphoma/© 2025, Atsunobu Takeda et al, Jpn J Ophthalmol, Antibody drug conjugates/© huenstructurebio.com / stock.adobe.com, Chest x-ray showing patchy infiltrates with internal lucency suggestive of cavitation/© 2025, Akela Ghazawi et al, BMC Infect Dis, Doctor examining man's neck with a dermatoscope/© yacobchuk / Getty Images / iStock (symbolic image with models)